BRCA1/2 testing is only recommended for certain population or individuals with a high risk of having a BRCA1/2 gene mutation, including those with:
The BRCAtest provides valuable information that can be utilized for reducing the risk of cancer development or recurrence by assisting the treating physicians to individualize surgical and pharmaceutical management. In addition, it can be used to identify those family members at risk of developing cancer who can benefit from risk reduction management. Furthermore, those family members that do not carry the pathogenic mutation identified in the family can be relieved of the stress of developing hereditary cancer and forego unnecessary interventions.
This test covers mainly breast (male and female) and ovarian cancer. In addition, some mutations may increase the risk of pancreatic and prostate cancer, as well as melanoma.
The results obtained by the test are useful for the entire family. When a pathogenic mutation is identified in the majority of cases it is inherited from one of our parents. Siblings and children also have 50% risk of having inherited the same pathogenic mutation. More distant relatives, such as cousins, aunts and uncles and grandparents, are also at risk of carrying the pathogenic mutation identified in your sample even if they have not yet been diagnosed with cancer or if they have a different type of cancer than the one diagnosed in you. Knowledge about this predisposition can help guide their surveillance plan, leading to earlier detection of cancer at a stage when it is more easily managed.
Note that hereditary cancer predisposition syndromes can be associated with many different types of cancer. This means, that even if the mutation detected in your sample is mostly associated with breast or ovarian cancer it can also increase the risk of prostate or pancreatic cancer, for example. This in turn means that the knowledge about carrying a pathogenic mutation is equally important for both male and female relatives. Please ask your physician to help you identify which relatives should be tested for the mutation identified.
The results will be available in 15 working days.
Whole peripheral blood in EDTA vials. (2 vials)
For information about the cost coverage of the test you should contact your personal insurance.
The payment can be made by bank transfer or credit/debit card.
No, Genekor DOES NOT perform blood sample collections so you need to contact your doctor or any other laboratory which performs this kind of collections so you can get the sample.
Genekor Medical S.A. is certified with ELOT EN ISO9001:2008 and ELOT EN ISO15189:2012, which require the written consent of each patient for the use of his/her genetic material for testing.
A negative report indicates that no clinically significant mutation has been identified. In this report you will find an interpretation of the findings along with details about non-clinically significant variants.
A positive report indicates that a pathogenic mutation was identified. In this report you will find details about the variant detected and extensive interpretation of the risk of the individual, along with analysis of the findings.
A VUS (Variant of Uncertain Clinical Significance) report indicates that the available data (published and in silico analyses) are not enough to characterize the variants identified in this individual, as pathogenic or benign. In these cases, clinical management should be based on personal and family history. VUS results should not be used in predictive testing of at risk relatives.
Ask your physician if you are eligible for the BRCA Germline test.
A blood sample is required for this test (2 EDTA vials). Your sample will be collected per your physican's instructions.
Your sample will arrive to to our accredited laboratory and your report will be generated and released to you and your physician in 15 days
Your report will be electronically released to your physician via email and/or uploaded to our secure portal, and to you via mail.